HOMA, BMI, and Serum Leptin Levels Variations during Antiviral Treatment Suggest Virus-Related Insulin Resistance in Noncirrhotic, Nonobese, and Nondiabetic Chronic Hepatitis C Genotype 1 Patients

Table 3

Baseline pretreatment variables based on treatment outcome (SVR) at univariate and multivariate analyses.

	Univariate analysis				Multivariate analysis
	SVR	Non-SVR	OR 95% CI		OR 95% CI
Number of patients	26	49
Age (median; range)	48 (26–67)	49 (31–67)	1.07 (1.02–1.12)	0.008	1.26 (0.99–1.60)		0.051
Sex (M/F)	16/10	29/20	0.91 (0.34–2.4)	0.84
BMI (median; range)	22.7 (19.4–29.1)	24.2 (21.3–29.6)	1.33 (1.07–1.66)	0.01	1.05 (1.00–1.11)		0.041
Fasting glucose (median; range)	4.86 (2.41–6.23)	5.1 (2.2–6.88)	1.16 (0.76–1.79)	0.49
Fasting insulin (median; range)	8.0 (1.41–24.1)	8.9 (2.90–33.1)	0.98 (0.93–1.04)	0.58
HOMA-IR (median; range)	1.93 (0.3–10.3)	2.25 (0.3–10.5)	0.95 (0.77–1.18)	0.65
Leptin (median; range)	6.3 (2.2–29.2)	15.4 (3–55)	1.01 (0.96–1.05)	0.89
Adiponectin (median; range)	12.2 (4.5–23.3)	17.05 (7.1–36.1)	1.02 (0.94–1.10)	0.67